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Introduction: Dengue is vector-borne viral infection that endangers an estimated 2.5 
billion people. Disease caused by dengue ranges from a relatively minor febrile illness 
to a life-threatening condition characterised by extensive capillary leak. A greater 
understanding of dengue has the potential to improve both the clinical management of 
individual cases and the control of the disease. 
 
Sources of data: We searched the available literature suing PubMed, Embase and 
Web of Science for relevant articles and abstracts. 
 
Areas of agreement: Addressing our gaps in the understanding of disease 
pathogenesis and improving our knowledge of dengue virus biology are necessary in 
order to develop tools to effectively control, diagnose and treat the disease. 
 
Areas of controversy: The pathogenesis of dengue is multifactorial and depends on 
both host and virus factors. A more integrated understanding of disease pathogenesis 
is necessary. 
 
Areas timely for developing research: There are many questions related to disease 
pathogenesis, development of diagnostics, drug and vaccine development and 
individual case management that need addressing if the disease is to be successfully 
tackled. 
 
Keywords: Dengue / Dengue Haemorrhagic Fever / Dengue Shock Syndrome / 
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Introduction 
 
Dengue is a viral infection transmitted by Aedes mosquitoes.1 Dengue is a Flavivirus 
with four different antigenically distinct serotypes (DENV1-4).2, 3 It is a rapidly 
growing health problem with an estimated 2.5 billion people at risk, mainly in 
countries of south and south-east Asia, the Caribbean, Central and South America, 
and more recently in Africa.4, 5 The spread of dengue is thought to be due to 
combination of factors: increased urbanisation, population growth, migration and 
international travel and the difficulties of effective vector control.6 Climate change 
may be a contributing factor in the global spread of dengue.7 It is estimated that there 
are between 50 and 100 million cases of dengue each year, of which approximately 
500,000 are severe life-threatening infections.8 There have been numerous urban 
outbreaks of dengue with significant health and economic impacts.9-11 Studies in 
Thailand and Brazil have shown that the social and economic impact is equivalent to 
that of malaria in these countries.12, 13 However globally dengue research has not 
received the same level of funding as other tropical infectious diseases.8 There are 
currently no available drugs, no licensed vaccine and diagnosis in endemic areas is 
largely clinical.14 Dengue also poses a risk to those who travel to endemic areas and is 
increasingly being reported in travellers returning from trips to endemic countries.15 
 
Dengue viruses cause a variety of clinical syndromes ranging from asymptomatic 
infection to a self-limiting febrile illness to severe dengue, a life-threatening condition 
characterised by increased capillary permeability and shock.16-18 There are concerns 
that the old WHO definitions of dengue that are still in widespread use may lead to 
under-diagnosis of severe dengue.19 In clinically apparent dengue infection symptoms 
develop after an incubation period of 4 to 7 days with an abrupt onset of fevers often 
accompanied by headache with severe retro-orbital pain.20, 21 Some patients develop 
severe arthralgia, explaining the historical name of break-bone fever.22 Early in the 
illness the skin may appear flushed, with petechiae appearing during the ‘critical 
phase’ and a macular rash appearing in early convalescence. Even after 
uncomplicated dengue recovery may be complicated by fatigue and depression. 
Thrombocytopenia is almost universal in dengue infection and minor bleeding from 
skin and mucosal surfaces may be seen in uncomplicated infections - this can be 
severe in patients with peptic ulcer disease.23 Biochemical hepatitis is frequently seen 
in dengue infection but severe liver pathology, encephalitis and renal dysfunction are 
relatively rare.21, 24 Data from Taiwan show differences in disease manifestations 
between adults and children observed during an outbreak in 2002.25 Arthralgia, 
headache, gastrointestinal bleeding and significantly severe dengue were more 
common in adult patients. The reasons for these differences are not clear but could 
reflect differences in the host response to infection. Significant and disabling fatigue 
has been described after recovery from dengue.26 It is thought that host factors may 
contribute to the development of this condition. Vertical transmission of dengue can 
occur if infection of the mother occurs within 8 days of delivery.27 The WHO have 
recently published new guidelines on dengue management.28 The new guidelines 
indicate that disease caused by dengue encompasses a wide clinical spectrum and that 
the previously used classifications for severe dengue were not always helpful. Dengue 
is classified in the new system as either uncomplicated or severe.28  Severe disease is 
characterised by plasma leak, haemorrhage and organ impairment. Recognising 
warning signs for severe disease is important for successful clinical management. 
Warning signs include abdominal pain, evidence of fluid accumulation, 
hepatomegaly, and increases in haematocrit accompanied by fall in platelet count.28 
The mechanisms that lead to severe dengue are not completely understood although 
various hypotheses exist. Perhaps the most widely accepted hypothesis explaining the 
development of severe dengue is that of antibody-mediated immune enhancement 
where antibodies developed to a previous infection lead to enhanced viral uptake with 
a new infection of a different serotype.29, 30 This and other hypotheses will be 
discussed in a later section of this review. 
 
Sources of data 
We searched the available literature up to April 2010 using PubMed, Web of Science 
and Embase using the terms: "dengue"; "dengue fever"; "dengue haemorrhagic fever"; 
and "dengue viruses". 
 
Areas of agreement 
As dengue has emerged as a global health threat it has received increased attention 
from the international public health community.14 Essentially areas of agreement are 
based around addressing the lack of effective diagnostic and therapeutic options, 
improving clinical care of affected patients, and developing tools to prevent dengue 
infection. 
 
 
Areas of controversy 
Is the virus itself or the host response to infection the main cause of severe disease? 
The 4 serotypes of dengue can be further classified into different genotypes based on 
nucleotide variation.31 Different genotypes have been associated with different levels 
of virulence.32, 33 It appears that the virus may evolve during epidemics to cause more 
severe disease as seen in disease outbreaks in Cuba and Australia.34, 35 It has been 
suggested that structural differences in strains of the virus lead to differing abilities to 
infect different cell types or cause severe disease.36, 37 However given that only a 
small percentage of patients infected with dengue develop severe disease it is clear 
that host factors have a major role to play in dengue pathogenesis.31 
 
Many of the clinical features of dengue infection may be due to the patients' immune 
response.  The increased vascular permeability seen in dengue is associated with high 
levels of cytokines including tumour necrosis factor alpha (TNF-), interferon 
gamma (IFN-), interleukin six (IL-6) and interleukin two (IL-2).38, 39 However, it is 
important to note that these cytokines are elevated in many diseases yet dengue is a 
very specific clinical entity. Therefore the clinical features of dengue could be due to 
a specific constellation of these cytokines or a more complex interaction between host 
and virus that is yet to be characterised. Polymorphisms in TNF- are associated with 
more severe disease.40 Various other genetic factors have been associated with more 
severe disease: for example polymorphisms in the vitamin D receptor gene, the 
mannose-binding lectin gene, and various HLA class I and II alleles.41-44 However, 
none of these studies have been large enough to indicate a clear association and the 
question of host susceptibility remains unanswered. Cytokine dysregulation and 
endothelial injury contribute to the pathogenesis of yellow fever, another flavivirus.45 
The pathophysiology of severe yellow fever infection remain unclear, but given 
similarities with severe dengue there may be overlap in the host and virus 
determinants of susceptibility. 
 
  
Is the hypothesis of antibody-mediated enhancement sufficient to explain the 
development of severe disease? 
Epidemiological studies have shown that severe disease is more commonly seen after 
secondary infections.46 Infection with one serotype is thought to result in brief 
protection against all serotypes. As the levels of neutralising antibodies fall over time 
the non-neutralising or sub-neutralising antibodies form complexes with the new 
infecting virus and these complexes are taken up by Fc-receptor bearing cells. This 
results in increased uptake of virus, increased replication and viral load and hence a 
postulated increased likelihood of complications.30 This phenomenon explains the 
severe disease observed in infants aged between 6 and 9 months where the low non-
neutralising levels of maternally derived antibodies are thought to play a crucial role 
in the development of severe disease.47, 48 These observations have led to concerns 
that a vaccine may potentially result in more severe disease by priming the immune 
system and putting individuals at risk when they are subsequently infected.  These 
fears are ungrounded if such a vaccine produces long term neutralising protection to 
all 4 serotypes and those serotypes do not change over time.3 However, severe disease 
can occur in primary infections and most secondary infections do not result in severe 
disease indicating that other factors contribute.49,50,51 Direct evidence for antibody-
dependent enhancement (ADE) contributing to the development of severe disease in 
humans has been difficult to demonstrate although recent work in infants and from 
elegant in vitro and clinical studies is starting to yield crucial insights into how ADE 
may contribute to pathogenesis.51, 52 
 
The pathogenesis of dengue is complex and multifactorial. No hypothesis in isolation 
is sufficient to explain the development of severe disease. It is the interplay between 
virus factors and genetically determined host factors that determine the disease 
outcome in the individual patient.  
 
Growing points - areas timely for developing research 
Increased understanding of dengue pathogenesis 
As discussed above the mechanisms that lead to severe dengue are incompletely 
understood. A greater and clearer understanding of disease pathogenesis including 
host genetics, virus biology and immunopathology, would help the development of 
targeted clinical interventions.14 Clarifying how dengue virus virulence varies 
between serotypes and evolves within epidemics would be helpful. Do different 
serotypes vary in their tissue tropism thus explaining differences in disease severity? 
Elucidating how the different factors within the immune system interact and 
contribute to disease development is essential. Too often research focuses on a single 
aspect of the immune response, be it antibody-mediated enhancement, T and B cell 
responses or the role of complement when a more integrated view, including 
consideration of the virus, is required.31  
 
NSI is a glycoprotein secreted by dengue-infected cells. Early detection of NSI has 
demonstrated efficacy as a diagnostic tool.54 Its role in dengue pathogenesis is unclear 
– defining this role may lend weight to its use in diagnostics. It is possible that it 
activates complement at endothelial surfaces thus contributing to the vascular leak 
that occurs in severe disease.55 Clarifying the events that occur at the endothelial 
surface in dengue infection would be a major advance - the development of a suitable 
animal model of dengue infection would aid this progress.56 
 
An increased understanding of genetic factors that contribute to disease development 
would help define more clearly populations at risk. Within populations an increased 
understanding of differing susceptibilities to disease development is necessary.31 
 
Optimisation of clinical management 
The commonly used WHO guidelines for the management of dengue were developed 
after observations in children hospitalised in Bangkok in the 1960s with dengue.19 
These guidelines have evolved over the years and have been adopted into clinical 
practice in endemic areas. An attempt to validate the WHO classifications for severe 
disease has been recently published.57 This study showed that while the WHO 
classifications had good specificity for severe disease the sensitivity was lower. There 
is no doubt that the use of the guidelines have led to substantial mortality reductions, 
yet are guidelines originally developed for Thai children forty years ago still 
applicable today or for example in the increasing number of adult patients seen 
globally?19, 58 
 
One of the difficulties diagnosing dengue haemorrhagic fever (DHF) using the old 
WHO definitions was that the criteria were too rigid.16 Studies have shown that many 
cases of dengue that resulted in shock or death did not meet the WHO case 
definitions.59, 60 These problems have led to the development of the new WHO 
guidelines that categorise dengue cases into uncomplicated or severe.28 These 
guidelines emphasise the importance of recognising the warning signs of severe 
dengue - abdominal pain, vomiting, fluid accumulation, mucosal bleeding, lethargy or 
restlessness, hepatomegaly, rising haematocrit in conjunction with falling platelets.28 
These 2009 WHO guidelines include a detailed description of the clinical 
management of dengue including an algorithm for the management 
(http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf).  A challenge 
is educating healthcare workers about the new guidelines and ensuring that they result 
in better clinical care. 
  
The mortality in severe dengue remains significant particularly in infants.50, 61 In 
addition higher mortality rates are seen when dengue newly emerges in regions where 
there is less experience in clinical management of cases, for example as seen in the 
epidemics in India and Brazil.10, 62 Fluid management in dengue is difficult - the 
balance between too much and too little is critical and getting it wrong can be life-
threatening.63 Fluid resuscitation is not without risk and fluid overload in the recovery 
phase can cause acute respiratory distress syndrome (ARDS).28   Fluid management in 
patients with co-morbidities or pregnancy is difficult and would benefit from further 
research. 
 
It is likely that there is a significant unreported burden of mortality in remote health 
facilities where clinical management maybe poor. Early and careful administration of 
parenteral fluids is life saving in severe dengue. Ringer's lactate has demonstrated 
efficacy for use in dengue shock syndrome and dextran or starch have also been 
suggested for severe disease.64 Successful management of severe dengue requires 
favourable staff to patient ratios and the ability to closely monitor patients.28 
Unfortunately the use of parenteral fluids and the intense monitoring that is required 
may not always be available and there is a need for research on the use of oral 
rehydration therapy aimed at preventing the development of shock in severe dengue.14  
 
The endothelial leak seen in severe dengue is transient and if appropriate supportive 
therapy is given during this period mortality rates are low.16 However in the early 
stages of disease clinical features are non-specific and are shared with other infectious 
aetiologies.61 Making a diagnosis early in the disease would significantly aid clinical 
management. Additionally predicting which patients are at risk of severe disease 
would be a major advance. Traditionally diagnosis has relied on serology, which can 
take time to give useful results meaning diagnosis is often retrospective.1 IgM against 
dengue can be detected after 5 days of fever - commercially available diagnostic kits 
based on ELISA have been assessed.65 These have potential but have limitations, for 
example the persistence of IgM in some patients in endemic areas making it difficult 
to diagnose an acute infection. The detection of the dengue protein NSI also has 
proven use in diagnosis.54 Quantifying the titre of NSI early in clinical illness may 
allow one to predict those at risk of developing severe disease.66 Real-time PCR is 
another potential, highly sensitive diagnostic tool in dengue diagnosis.67 However the 
cost of molecular tests such as PCR make it an impractical tool for use in many 
settings where dengue is prevalent.  A rapid sensitive test that combines detection of 
NS1, IgG and IgM allowing diagnosis of infection throughout the illness course 
would be a major advance in dengue diagnostics. The development of appropriate 
clinical algorithms for use in resource-limited settings in parallel to the development 
of molecular diagnostic tools is necessary if the burden of dengue is to be adequately 
dealt with. A study has demonstrated the potential use of a decision tree algorithm 
using simple clinical and haematological parameters.68 Testing the validity of such an 
algorithm in primary care settings have the potential to improve the triage and initial 
clinical management of patients with dengue. Detection of plasma leakage through 
serial ultrasound is a useful adjunctive tool in dengue diagnosis and management yet 
it is unlikely to be of benefit in many areas due to lack of availability.69 Identifying 
additional predictors of dengue would be useful - making these into diagnostic 
techniques that are practical in resource-limited settings is the challenge.70  
 
Vaccine development 
A vaccine against dengue would be a major advance in the control of the disease. In 
view of the potential risks of antibody-mediated enhancement seen with heterotypic 
infections a successful vaccine would have to offer lasting protection against all 4 
serotypes.2 Based on the success of vaccination against other flaviviruses, for example 
Japanese encephalitis and yellow fever, the development of a live attenuated vaccine 
had previously been the most promising prospect for vaccinologists.71 However 
despite encouraging results with monovalent vaccines in clinical trials the 
development of a tetravalent formulation has proved problematic and development 
has been suspended.3, 72-75  The leading vaccine candidate at present is a chimeric 
vaccine - a recombinant clone based on yellow fever vaccine strain with dengue virus 
membrane and envelope protein genes substituted into the construct.76, 77 This 
chimeric vaccine has shown promise in Phase II clinical trials and appears safe and 
immunogenic.  It is anticipated that Phase III trials will start in the near future.   
 
Despite promising progress there remain unanswered questions that need to be 
addressed and are potential areas for research. The lack of a suitable animal model of 
dengue infection hinders the transfer of laboratory findings into clinical practice.31 
How do we quantify immune protection? Do tetravalent vaccine constructs hinder the 
development of immunity to individual serotypes? Could a dengue vaccine render 
populations more vulnerable to severe infection, either through antibody-mediated 
enhancement or via a mechanism similar to that seen with vaccines against respiratory 
syncytial virus?78 How safe are dengue vaccines in different subsets of the 
population?3  
 
In addition to the science of vaccine development and questions regarding the safety 
and efficacy of individual vaccine candidates there needs to be sustained co-
ordination between different countries and vaccine developers if a vaccine is to be 
successfully developed.79  
 
Anti-dengue drugs 
A greater understanding of dengue virus biology has meant that targets within the 
lifecycle have been identified that could potentially be the site of a therapeutic 
agent.80 The staggering success in developing drugs against HIV is an example of 
how efficiently effective antivirals can be developed given appropriate funding.   
 
One potential mechanism of action of an anti-dengue drug is through inhibition of 
viral entry. The fusion of the viral membrane with the host membrane is mediated by 
dengue virus E protein.81 Research has shown some promising initial results in 
laboratory studies with an experimental entry inhibitor - these findings could pave the 
way to the development of successful therapeutic agents.82 Other potential targets 
receiving research attention are the viral proteins NS3 and NS5, which play an 
integral role in genome replication - their protease domains could be target for 
protease inhibitors.83, 84 A computer programme has been used to identify suitable 
molecules that can "dock" into the NS3 protease domain.85 The challenge is to bridge 
the gap between findings in the laboratory and the bedside however given the 
progress in our understanding of dengue virus biology the future of drug development 
is encouraging.  There are potential therapeutic developments for the treatment of 
other flaviviruses such as hepatitis C.86 In view of structural similarities between 
different flaviviruses these developments could be used in the field of dengue 
treatment. The complications of dengue occur as the virus is cleared from the blood so 
it is possible that an anti-dengue drug will have no beneficial role. As the severe 
manifestations of disease are in part due to the immune response perhaps the 
development of an immunomodulatory agent would be the best therapeutic strategy? 
Animal studies have shown the protective effect of monoclonal antibodies against the 
NS1 protein of West Nile virus, and more recent work in mice has shown the 
therapeutic potential of a monoclonal antibody directed against a structural epitope in 
an experimental DENV-1 infection.87, 88 
 
Vector control 
In addition to vaccination successful vector control would be a useful adjunct to 
controlling dengue. Dengue is closely associated with Aedes aegypti - the global 
spread of dengue is related to changes in human behaviour, in particular the 
expansion of large urban centres, that support the breeding of A. aegypti.6 While 
vector control has previously had success the persistence of pockets of mosquitoes 
resulted in disease re-emergence.89 Studies have shown different efficiencies of 
dengue transmission between different mosquito strains and different serotypes of 
dengue.90, 91 A greater understanding of the interactions between mosquitoes and the 
different serotypes of dengue would give us a greater understanding of transmission 
dynamics and would potentially lead to better prediction of epidemics and thus better 
control of the disease. The development of genetically modified mosquitoes that are 
less able to transmit dengue is a potential option for disease control. However 
mathematical models have indicated that this strategy may select for greater disease 
virulence suggesting that measures that increase mosquito mortality may be more 
effective.92 Transgenic mosquitoes are likely to be less reproductively fit - infection of 
transgenic mosquitoes with the symbiont Wolbachia potentially confers a 
reproductive advantage thus allowing the establishment of transgenics in the 
environment.93 Cyclopoid copepods are invertebrate predators of mosquito larvae. 
Introduction of copepods into water containers, the typical breeding site of Aedes, can 
have a major impact on mosquito populations.94 The roll out of larvicidal 
interventions requires active community involvement and the success of such 
measures would depend on imaginative public health engagement.94 
 
Conclusions 
Successfully tackling the threat of dengue represents a major public health challenge 
for the 21st century. A coordinated multidisciplinary approach is necessary. Major 
advances are possible provided dengue research receives the attention and funding its 
prevalence deserves. 
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